{"id":"NCT01243177","sponsor":"UCB BIOSCIENCES GmbH","briefTitle":"Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older","officialTitle":"A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04","primaryCompletion":"2015-07","completion":"2015-08","firstPosted":"2010-11-18","resultsPosted":"2016-02-23","lastUpdate":"2021-02-02"},"enrollment":888,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy","Monotherapy"],"interventions":[{"type":"DRUG","name":"Lacosamide","otherNames":["Vimpat®"]},{"type":"DRUG","name":"Carbamazepine-Controlled Release","otherNames":["Tegretol® Retard Tablets 200 mg"]}],"arms":[{"label":"Lacosamide","type":"EXPERIMENTAL"},{"label":"Carbamazepine-Controlled Release (CBZ-CR)","type":"ACTIVE_COMPARATOR"}],"summary":"Compare efficacy and safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with a primary efficacy endpoint of 6-month seizure freedom. Noninferiority design to show a similar risk/benefit balance between Lacosamide (LCM) and Carbamazepine-CR (CBZ-CR).","primaryOutcome":{"measure":"Proportion of Subjects in the Full Analysis Set (FAS) Remaining Seizure Free for 6 Consecutive Months (26 Consecutive Weeks) of Treatment Following Stabilization at the Last Evaluated Dose for Each Subject","timeFrame":"6 consecutive months (26 consecutive weeks) of treatment following stabilization at the last evaluated dose for each subject","effectByArm":[{"arm":"Lacosamide","deltaMin":89.8,"sd":null},{"arm":"Carbamazepine-Controlled Release (CBZ-CR)","deltaMin":91.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":184,"countries":["United States","Australia","Belgium","Bulgaria","Canada","Czechia","Finland","France","Germany","Greece","Hungary","Italy","Japan","Latvia","Lithuania","Mexico","Philippines","Poland","Portugal","Romania","Russia","Slovakia","South Korea","Spain","Sweden","Switzerland","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["27889312","33200428","28290119"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":444},"commonTop":["Headache","Dizziness","Fatigue","Somnolence","Nasopharyngitis"]}}